Records 1 - 12
| Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
European journal of cancer (Oxford, England : 1990) 2018 Jun 99 66-77.
Tejpar Sabine, Yan Pu, Piessevaux Hubert, Dietrich Daniel, Brauchli Peter, Klingbiel Dirk, Fiocca Roberto, Delorenzi Mauro, Bosman Fred, Roth Arnaud
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
BMC cancer 2017 Jun 17 (1): 437.
Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L
| UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun 79 (6): 1109-1117.
Chen Xuewei, Liu Liping, Guo Zhihua, Liang Wenhua, He Jiaxi, Huang Liyan, Deng Qiuhua, Tang Hailing, Pan Hui, Guo Minzhang, Liu Yang, He Qihua, He Jianxi
| Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
The Journal of pharmacology and experimental therapeutics 2013 Apr 345 (1): 95-101.
Lévesque Eric, Bélanger Anne-Sophie, Harvey Mario, Couture Félix, Jonker Derek, Innocenti Federico, Cecchin Erica, Toffoli Giuseppe, Guillemette Chant
| Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
The Tohoku journal of experimental medicine 2013 229 (2): 107-14.
Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi
| The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Cancer chemotherapy and pharmacology 2012 Jun 69 (6): 1591-9.
Lamas M J, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez J M, Lopez R, Carracedo A, Barros
| Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6.
Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N
| UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
British journal of cancer 2010 Aug 103 (4): 581-9.
Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano J L, Moreno
| [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2007 Dec 29 (12): 913-6.
Wang Yan, Xu Jian-Ming, Shen Lin, Xu Nong, Wang Jin-Wan, Jiao Shun-Chang, Zhang Jing-Sheng, Song San-Tai, Li Jian, Bao Han-Ying, Yang Lin, Li Fa
| Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Clinical colorectal cancer 2007 Jul 6 (8): 583-7.
Fakih Marwan G, Ross Mary Ellen, Starostik Pe
| Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Pharmacogenetics and genomics 2007 Jul 17 (7): 497-504.
Minami Hironobu, Sai Kimie, Saeki Mayumi, Saito Yoshiro, Ozawa Shogo, Suzuki Kazuhiro, Kaniwa Nahoko, Sawada Jun-ichi, Hamaguchi Tetsuya, Yamamoto Noboru, Shirao Kuniaki, Yamada Yasuhide, Ohmatsu Hironobu, Kubota Kaoru, Yoshida Teruhiko, Ohtsu Atsushi, Saijo Nagahi
| Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 May 24 (15): 2237-44.
Han Ji-Youn, Lim Hyeong-Seok, Shin Eun Soon, Yoo Yeon-Kyeong, Park Yong Hoon, Lee Jong-Eun, Jang In-Jin, Lee Dae Ho, Lee Jin S